Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
FDA sets target action date of June 1, 2021BASEL, Switzerland, Aug. 17, 2020 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a […]